AstraZeneca has announced a Rs. 176 crore investment to expand its Global Innovation and Technology Centre (GITC) in Chennai, underscoring India’s strategic importance in the company’s global research and development ecosystem. The expansion will enhance capabilities in clinical trials, manufacturing technologies, and biopharmaceutical innovation, enabling AstraZeneca to accelerate drug development and optimize supply chains.